TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT03394365: A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemo

Sponsor: Pierre Fabre Medicament · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 115 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,630,088

Rescue Site Savings

+$2,404,344

Unlock Full NCT03394365 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT03394365 Rescue Dossier →